29 Sep 2008 | 11:02
Suven completes phase-I clinical trials single ascending dose of SUVN-502
Suven Life Sciences has completed the phase-I single ascending dose study of SUVN-502 in healthy subjects. SUVN-502 is a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like attention deficient hyperactivity, Parkinson, Schizophrenia. The study was conducted at Basel, Switzerland under a clinical trial application approved by SwissMedic, the regulatory authority of Switzerland for therapeutic products. The study is A double-blind, placebo-controlled, randomized, single ascending dose study in healthy male subjects.
The tolerability of SUVN-502 up to the highest dose administered is very good. No serious adverse events occurred. No clinically significant changes or study medication related abnormalities were observed with respect ECGs and laboratory evaluations. There were no clinically significant changes of vital sign parameters. The detailed pharmacokinetics of the SUVN-502 was studied from the blood samples drawn up to 72 hours post-dosing. SUVN-502 demonstrated very favorable pharmacokinetics with a potential for once in a day dosing.
The company made this announcement during the trading hours today, 29 September 2008.
Suven completes phase-I clinical trials single ascending dose of SUVN-502
Suven Life Sciences has completed the phase-I single ascending dose study of SUVN-502 in healthy subjects. SUVN-502 is a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like attention deficient hyperactivity, Parkinson, Schizophrenia. The study was conducted at Basel, Switzerland under a clinical trial application approved by SwissMedic, the regulatory authority of Switzerland for therapeutic products. The study is A double-blind, placebo-controlled, randomized, single ascending dose study in healthy male subjects.
The tolerability of SUVN-502 up to the highest dose administered is very good. No serious adverse events occurred. No clinically significant changes or study medication related abnormalities were observed with respect ECGs and laboratory evaluations. There were no clinically significant changes of vital sign parameters. The detailed pharmacokinetics of the SUVN-502 was studied from the blood samples drawn up to 72 hours post-dosing. SUVN-502 demonstrated very favorable pharmacokinetics with a potential for once in a day dosing.
The company made this announcement during the trading hours today, 29 September 2008.
0 comments:
Post a Comment